The INVITE-Home Study is exploring new ways for people with HIV to receive Cabenuva, a long-acting injectable antiretroviral therapy (LAI-ART). Instead of having to visit a doctor’s office every month or two, participants will be able to choose a trusted friend or family member to learn how to give the injections at home.
This study responds to a critical need for alternative, decentralized delivery options for LAI-ART. Our goal is to make treatment easier to access and maintain, improve real-world effectiveness, reduce systemic barriers, and help close persistent gaps in HIV care.
In collaboration with funders at the Centers for Disease Control and Prevention. UCSF researchers on the INVITE-Home Study will conduct the study in 2 parts:
In Aim 1, we designed and developed an innovative treatment buddy training to support the acceptability and uptake of LAI-ART at home. We interviewed people with HIV, treatment buddies, and clinicians to understand their needs and potential challenges, which directly informed the training.
To further refine the approach, we conducted a pilot study with seven people with HIV and their treatment buddies, which demonstrated the feasibility of home injections administered by treatment buddies.
In Aim 2 (beginning February 2026), we will build on this work to test the training program developed in Aim 1. This phase will examine the implementation and effectiveness of home-based LAI-ART injections delivered by treatment buddies.